

Original Research

Chronic Bronchitis in COPD Patients Creates Worse Symptom Burden Regardless of the Presence of Bronchiectasis in the COPDGene Cohort

Oksana Bohn, MD¹ Min Xi, MS² Natalie K. Woodruff, BS² Gary L. Hansen, PhD^{2,3}
Charlene E. McEvoy, MD, MPH^{2,3} and the COPDGene[®] Investigators

Abstract

Purpose: To assess whether the presence or absence of bronchiectasis has an impact on the patient-reported symptoms of chronic obstructive pulmonary disease (COPD) patients.

Methods: The study included participants from the COPD Genetic Epidemiology Study (COPDGene[®]) cohort with available high-resolution chest tomography reporting the presence or absence of bronchiectasis (BE+/BE-) and survey data reporting the presence or absence of chronic bronchitis symptoms (CB+/CB-). Patient symptoms based on the St George's Respiratory Questionnaire (SGRQ) were then compared for the different groups.

Results: The study population included 7976 participants, mean age 60, Global initiative for chronic Obstructive Lung Disease (GOLD) stages 0 to 4, 18.8% BE+, and 19.5% CB+. The presence or absence of radiographic bronchiectasis was not associated with higher frequency of chronic bronchitis (GOLD 0 group odds ratio [OR] 1.01 [0.78,1.31], GOLD 1-2 group OR 1.19 [0.95, 1.50], GOLD 3-4 group OR 1.26 [0.99, 1.60]). Similarly, CB+ participants had higher SGRQ scores than CB- participants regardless of the presence of BE.

Conclusions: Across all GOLD stages, chronic bronchitis symptoms are associated with worse pulmonary symptoms and significant impairment in quality of life. For patients with chronic bronchitis, the presence or absence of bronchiectasis is not associated with a significant difference in SGRQ symptom scores. Symptoms of chronic bronchitis impose a heavy burden on patients and should be treated regardless of the presence or absence of underlying bronchiectasis.

Abbreviations: chronic obstructive pulmonary disease, **COPD**; COPD Genetic Epidemiology study, **COPDGene[®]**; confirmed presence of bronchiectasis, **BE+**; confirmed absence of bronchiectasis; **BE-**; confirmed presence of chronic bronchitis, **CB+**; confirmed absence of chronic bronchitis, **CB-**; St George's Respiratory Questionnaire, **SGRQ**; Global initiative for chronic Obstructive Lung Disease, **GOLD**; odds ratio, **OR**; Body mass index-Obstruction-Dyspnea-Exercise index, **BODE**; confidence interval, **CI**

Funding Support: This work was supported by funds from RespirTech to HealthPartners Institute.

Date of Acceptance: May 12, 2021 | **Published Online Date:** June 10, 2021

Citation: Bohn O, Xi M, Woodruff NK, Hansen GL, McEvoy CE; COPDGene investigators. Chronic bronchitis in COPD patients creates worse symptom burden regardless of the presence of bronchiectasis in the COPDGene cohort. *Chronic Obstr Pulm Dis.* 2021;8(3):350-359. doi: <https://doi.org/10.15326/jcopdf.2021.0202>

1 University of Minnesota, Minneapolis, Minnesota, United States

2 HealthPartners Institute, Bloomington, Minnesota, United States

3 RespirTech, a Philips company, St. Paul, Minnesota, United States

Keywords:

chronic bronchitis; bronchiectasis; St George's Respiratory Questionnaire; Global initiative for chronic Lung Disease; GOLD

Address correspondence to:

Charlene McEvoy, MD, MPH
 HealthPartners Institute
 8170 33rd Avenue South, MS23301A
 Bloomington, MN 55425
 Email: Charlene.E.McEvoy@HealthPartners.com
 Phone: (612) 845-6711

Note: An abstract of this work was presented at the 2017 CHEST conference.

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally.¹ In the United States, COPD ranks fourth in causes of mortality with over 150,000 deaths annually.² An estimated 15.5 million people had diagnosed COPD in 2015,³ and an estimated 12 million potential cases remain undiagnosed (44%).⁴ The estimated total annual cost of COPD for 2010 was \$49.9 billion.⁵

Chronic bronchitis symptoms related to COPD often bring patients into both primary and specialty care clinics.^{6,7} The presence of chronic bronchitis in persons with COPD is associated with negative patient outcomes such as more severe airflow obstruction, diminished quality of life, high rate of hospitalization, and early mortality.⁸⁻¹³ Despite the significant impact of chronic bronchitis symptoms on patients, there are very few management strategies available to patients who present with this disease phenotype.¹⁴

Another condition that is often associated with COPD is bronchiectasis, a pulmonary disorder characterized by permanent bronchial dilatation with associated inflammation, chronic cough, and recurrent exacerbations.¹⁵ There is substantial overlap between the populations with chronic bronchitis and bronchiectasis,^{16,17} but the direct effect of bronchiectasis on COPD patients with and without the symptoms of chronic bronchitis has not been adequately explored. Several past studies have examined the relationship between chronic bronchitis and symptoms using the COPD Genetic Epidemiology Study (COPDGene[®]) cohort, a large multicenter observational study designed to analyze genetic and clinical factors associated with COPD. Kim et al found the presence of chronic bronchitis symptoms was associated with higher St George's Respiratory Questionnaire (SGRQ) "Total" and

"Respiratory" scores.¹³ This study did not report other SGRQ domain sub-scores such as "Activity" and "Impact" and did not distinguish between patients with and without bronchiectasis. A subsequent abstract by Stewart et al examined COPDGene data based on the presence of bronchiectasis (BE+), finding that the BE+ phenotype was associated with more severe airflow obstruction, higher Body mass index-Obstruction-Dyspnea-Exercise (BODE) index, and more exacerbations.¹⁸ They did not stratify the bronchiectasis results by the presence of chronic bronchitis symptoms. Accordingly, this study estimates the full symptomatic burden of patients with COPD, stratified by the presence of both chronic bronchitis and bronchiectasis.

Methods

Data used in this study were extracted from the COPDGene cohort (ClinicalTrials.gov: NCT00608764). Characteristics of this cohort are published elsewhere.¹⁹ Succinctly, it includes over 10,000 persons with a history of smoking, Black and non-Hispanic White race, and aged 40 to 80 years. All participants undergo computed tomography imaging as well as extensive symptom characterization. The data also include self-reported information on cough and phlegm production, and chronic bronchitis, defined as the presence of cough and phlegm production for 3 months of the year for at least 2 consecutive years. The presence of bronchiectasis was identified via independent scoring by 2 chest radiologists. Bronchiectasis was defined as 1 or more of the following: (1) airway dilation, with the airway diameter greater than the adjacent pulmonary vessel, (2) abnormal airway tapering, or (3) location of a bronchus within 1 cm of the pleura. These criteria were assessed by multiple independent readers, who coded the presence of bronchiectasis as "yes," "no," or "equivocal."²⁰ This study met all criteria for institutional review board approval (HealthPartners Institute IRB #A07-127).

For this analysis, participants in the COPDGene cohort were divided into groups based on the presence or absence of chronic bronchitis (CB+/CB-) and bronchiectasis (BE+/BE-). The control cohort included those without either finding. Of the 10,729 persons in the full cohort,²¹ we identified 7976 participants for whom relevant imaging and

symptom data were available, including some patients without identifiable obstruction (“GOLD 0”).²² To assess the impact of chronic bronchitis on our participants, we then compared the available data regarding their COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages,²³ the presence of radiological bronchiectasis, and quality of life as measured by the SGRQ.²⁴ The latter included total scores as well as individual components: “Activity,” “Psychosocial Impact,” and “Symptom” sub-scores. The Symptom sub-score was left out of further analysis because its questions closely resembled the questions used to identify chronic bronchitis; comparing the 2 metrics would be tautological.

In order to provide an independent assessment of the presence of chronic bronchitis for the various patient populations, we compared the results for the “classic” American Thoracic Society definition used in this study²⁵ to similar criteria found in the SGRQ, following the method of Kim.²⁶ SGRQ chronic bronchitis was assigned if patients answered “almost every day” or “most days a week” to the following questions: “Over the last 4 weeks, I have coughed” and “Over the last 4 weeks, I have brought up phlegm (sputum).” The sensitivity for an SGRQ CB+ result given a classic CB+ result varies between 73% and 87% depending on the GOLD stage, while the corresponding specificity varies between 78% and 89% depending on the GOLD stage (Table 1), which demonstrates a close correspondence between the 2 methods.

Statistical Analysis

Differences between SGRQ scores for various combinations of bronchiectasis and bronchitis status were evaluated using the Mann-Whitney test for non-normal data and the *t*-test if data were normally distributed. Odds ratios (95% confidence interval [CI]) were calculated for the frequency of chronic bronchitis and bronchiectasis for different GOLD stages and was calculated using a 2x2 contingency table. All statistical analyses were conducted using the statistical software SAS v9.4 (SAS Inc.).

Results

Participants included in our analysis had a mean age of 60 (+9 years), were 54% male, and 69% self-

Table 1. Frequency Results for the Classic Definition of Chronic Bronchitis Versus Chronic Bronchitis Inferred from the St George’s Respiratory Questionnaire^a

	Classic Chronic Bronchitis		Sensitivity	Specificity
	CB-	CB+		
GOLD 0			87%	78%
SGRQ CB-	2938	108		
SGRQ CB+	454	373		
GOLD 1-2			79%	86%
SGRQ CB-	1490	86		
SGRQ CB+	390	511		
GOLD 3-4			73%	89%
SGRQ CB-	839	52		
SGRQ CB+	390	511		

^aSensitivity and specificity shown for the comparison of classic chronic bronchitis versus SGRQ inferred chronic bronchitis.

GOLD=Global initiative for chronic Obstructive Lung Disease; SGRQ=St George’s Respiratory Questionnaire; CB-=confirmed absence of chronic bronchitis; CB+=confirmed presence of chronic bronchitis

identified as White versus 31% as Black. Additional demographics are shown on Table 2. The data were segregated into 3 cohorts: GOLD stage 0 (3873, 48.6%), GOLD stage 1-2 (2477, 31.1%), and GOLD 3-4 (1626, 20.4%). Almost equal portions of the overall participant population had bronchiectasis (18.8%) and/or chronic bronchitis (19.5%). Within these subgroups, bronchiectasis (BE+) was found in higher proportions among progressively higher GOLD stages (19.5% in GOLD 0, 23.0% in GOLD 1-2, and 32.7% in GOLD 3-4). Similarly, chronic bronchitis (CB+) was also found in higher proportions among progressively higher GOLD stages (14.2% in GOLD 0, 31.8% in GOLD 1-2, and 41.4% in GOLD 3-4). The study cohort included participants who had combined chronic bronchitis and bronchiectasis (CB+/BE+), chronic bronchitis only (CB+/BE-), bronchiectasis only (CB-/BE+) and a control group with neither condition (CB-/BE-). Data show that the presence or absence of bronchiectasis was not associated with a higher frequency of chronic bronchitis (GOLD 0 group OR 1.01 [0.78,1.31], GOLD 1-2 group OR 1.19 [0.95, 1.50], GOLD 3-4 group OR 1.26 [0.99, 1.60]) (Table 3).

Table 2. Demographics for the Cohort Derived from Analysis of the COPDGene Study

Participant Population (n)	7976
Mean Age (years)	60 (+9)
Gender	
Male	4307 (54%)
Female	3669 (46%)
Race	
White	5516 (69.2%)
Black	2460 (30.8%)
GOLD Stage	
0	3873 (48.6%)
1–2	2477 (31.1%)
3–4	1626 (20.4%)
Bronchiectasis (BE+)	1496 (18.8%)
GOLD 0	632 (16.3%)
GOLD 1–2	463 (18.7%)
GOLD 3–4	401 (24.7%)
Chronic Bronchitis (CB+)	1554 (19.5%)
GOLD 0	481 (12.4%)
GOLD 1–2	597 (24.1%)
GOLD 3–4	476 (29.3%)
Oxygen Suppl.	991 (12.4%)
SGRQ Mean (SD)	
Overall	27.1 (22.9)
Active	39.0 (30.5)
Impact	18.7 (20.6)
Symptom	32.5 (26.0)

COPDGene=COPD Genetic Epidemiology study; GOLD=Global initiative for chronic Obstructive Lung Disease; BE+=confirmed presence of bronchiectasis; CB+=confirmed presence of chronic bronchitis; SGRQ=St George's Respiratory Questionnaire; SD=standard deviation

Individuals with progressively higher GOLD stages had overall higher SGRQ scores (Table 4A). Additionally, the data indicated that SGRQ scores were markedly higher among participants with chronic bronchitis symptoms (CB+) when compared to CB- participants within the same GOLD group; all differences were statistically significant (Table 4B).

Using these data, it was possible to compare the effect of bronchiectasis on SGRQ scores for patients with and without symptoms of chronic bronchitis (Figure 1). The results showed higher SGRQ Total scores among individuals with higher COPD GOLD stages and among CB+ participants across all GOLD stage groups and regardless of the presence of bronchiectasis (Figure 2). In all cases, the CB+/

Table 3. Distribution of Sub-types from the Cohort Derived from the COPDGene Study

A.			
	BE+	BE-	Odds Ratio
GOLD 0			1.01 ^a
CB+	79 (2%)	402 (10.4%)	[0.78, 1.31]
CB-	553 (14.3%)	2839 (73.3%)	
GOLD 1-2			1.19 ^a
CB+	124 (5%)	473 (19.1%)	[0.95, 1.50]
CB-	339 (13.7%)	1541 (62.2%)	
GOLD 3-4			1.26 ^a
CB+	132 (8.1%)	344 (21.2%)	[0.99, 1.60]
CB-	269 (16.5%)	881 (54.2%)	
B.			
	BE+	BE-	
GOLD 0			
% with CB+	12.5%	12.4%	
GOLD 1-2			
% with CB+	26.8%	23.5%	
GOLD 3-4			
% with CB+	32.9%	28.1%	

^aNon-significant

Odds ratios [95% confidence interval] are for the presence of bronchiectasis within the CB+ versus CB- groups. None of the differences are statistically significant. Percentages in parentheses are the proportion of patients with chronic bronchitis and bronchiectasis sub-type within each GOLD stage group.

COPDGene=COPD Genetic Epidemiology study; BE+=confirmed presence radiographic bronchiectasis; BE-=the confirmed absence of radiographic bronchiectasis; GOLD=Global initiative for chronic Obstructive Lung Disease; CB+=presence of chronic bronchitis; CB-=confirmed absence of chronic bronchitis

BE- groups had significantly elevated symptom scores while the BE+/CB- groups were similar to the control group (CB-/BE-).

Discussion

In the COPDGene cohort, individuals with chronic bronchitis had significantly poorer quality of life across all GOLD stages compared to those who do not. Our analysis of 7976 participants identified 1554 persons with symptoms of chronic bronchitis, representing 19.5% of our study cohort. This made chronic bronchitis a condition affecting a significant proportion of COPDGene population. The proportion of participants with chronic bronchitis was roughly

Table 4. St George's Respiratory Questionnaire Scores and Sub-scores for Different GOLD Stages^a

A.						
	SGRQ Active		SGRQ Impact		SGRQ Total	
	Mean (SD)	p-value	Mean (SD)	p-value	Mean (SD)	p-value
GOLD 0 (n=3873)	25.6 (25.7)	-	10.3 (15.4)	-	16.8 (17.9)	-
GOLD 1-2 (n=2477)	40.4 (28.1)	<0.0001	19.9 (19.9)	<0.0001	28.8 (21.6)	<0.0001
GOLD 3-4 (n=1626)	68.9 (21.4)	<0.0001	37.0 (20.4)	<0.0001	49.2 (18.8)	<0.0001
B.						
	SGRQ Active		SGRQ Impact		SGRQ Total	
	Mean (SD)	p-value	Mean (SD)	p-value	Mean (SD)	p-value
GOLD 0						
CB+	43.3 (28.3)	<0.0001	24.4 (21.2)	<0.0001	34.1 (21.4)	<0.0001
CB-	23.1 (24.3)		8.3 (13.2)		14.3 (15.9)	
GOLD 1-2						
CB+	54.0 (26.2)	<0.0001	32.3 (21.2)	<0.0001	43.1 (20.7)	<0.0001
CB-	36.1 (27.4)		15.9 (17.8)		24.2 (19.7)	
GOLD 3-4						
CB+	72.4 (21.4)	<0.0001	44.8 (20.6)	<0.0001	56.9 (18.4)	<0.0001
CB-	67.4 (21.3)		33.8 (19.4)		46.0 (18.0)	

^asegregated by the presence (CB+) or absence (CB-) of chronic bronchitis symptoms. SGRQ scores are shown as mean (\pm standard deviation)

SGRQ=St George's Respiratory Questionnaire; SD=standard deviation; GOLD=Global initiative for chronic Obstructive Lung Disease; CB-=confirmed absence of chronic bronchitis; CB+=confirmed presence of chronic bronchitis

similar to participants with radiographic evidence of bronchiectasis (18.8%), although it is notable that only 4.2% of our study population exhibited both bronchiectasis and chronic bronchitis, whereas 15.3% exhibited chronic bronchitis alone. Moreover, the data consistently demonstrated a negative impact of chronic bronchitis on the affected participants. Persons with chronic bronchitis reported higher SGRQ scores (i.e., worse) across all studied categories regardless of their COPD GOLD stage when compared to controls without chronic bronchitis. This is consistent with the results of Kim,¹³ who also found this relationship however, our study extends the results to the SGRQ "Impact" and "Active" scores, suggesting an even broader degradation in quality of life for these patients.

Furthermore, our data showed the presence of bronchiectasis had little impact on the patients' SGRQ scores, while the presence of chronic bronchitis had a major detrimental impact. Notably, the great majority of patients with bronchiectasis/COPD overlap did not have chronic bronchitis as defined by conventional criteria. Like the study of Stewart,¹⁸ our results suggest that bronchiectasis alone does not have a significant impact on participants' quality of life, and that bronchiectasis is not more

common in CB+ and CB- groups. We find that that chronic bronchitis may be a distinct phenotype that affects the SGRQ scores of persons with COPD regardless of any underlying structural disease. This result may be surprising in light of past work that shows a significant impact of bronchiectasis on other clinical variables.²⁷ We propose that excess sputum production is the primary factor affecting quality of life in persons with COPD, and that the presence of bronchiectasis, while it may contribute to retention of mucus, is a minor contributor. That is, patient-reported outcomes/symptoms better inform treatment options than radiographic reported structural changes.

This study was limited by the subjective nature of SGRQ score reporting. However, the data consistently show that persons with chronic bronchitis consistently exhibit more burdensome respiratory symptoms than controls at a similar GOLD stage. This work was also limited by the lack of clinical context behind the chronic bronchitis determination, including sputum color and quantity, any specific treatments the patient may have received, and the past record of exacerbations.

Current pharmaceutical treatments for COPD focus on improving forced expiratory volume in 1

Figure 1. St George's Respiratory Questionnaire Scores Grouped by GOLD Stage and the Presence or Absence of Chronic Bronchitis Symptoms





Figure 1A. shows SGRQ Active scores, Figure 1B. shows SGRQ Impact scores, and Figure 1C. shows SGRQ Total scores. Error bars are standard deviation. All differences are significant ($p < 0.0001$).

GOLD=Global initiative for chronic Obstructive Lung Disease; SGRQ=St George's Respiratory Questionnaire; CB+=presence of chronic bronchitis; CB-=confirmed absence of chronic bronchitis

Figure 2. St George's Respiratory Questionnaire Total Score Grouped by GOLD Stage and the Presence and Absence of Bronchiectasis and of Chronic Bronchitis



The control group (CB-/BE-) lacks both chronic bronchitis and bronchiectasis. Error bars are standard deviation. All differences are statistically significant when compared to the control except for one group: GOLD 1-2 CB-/BE+, $p=0.14$ (*).

GOLD=Global initiative for chronic Obstructive Lung Disease; SGRQ=St George's Respiratory Questionnaire; CB-=confirmed absence of chronic bronchitis; CB+=confirmed presence of chronic bronchitis; BE+= confirmed presence of bronchiectasis; BE-=confirmed absence of bronchiectasis

second, dyspnea, and exacerbations, while there are few options specifically for chronic bronchitis, and these are often costly and not well-tolerated.²⁸ At the same time, recent research suggests that reduction of symptoms is associated with fewer exacerbations and reduced exacerbation rates in patients with bronchiectasis.²⁹ Patients with symptoms of chronic bronchitis, with or without bronchiectasis, should receive appropriate treatment for their symptoms, which may include mucoactive therapies,^{28,30-32} inhaled corticosteroids,¹⁴ macrolides,¹⁴ bronchodilators,¹⁴ and airway clearance.^{14,33-35} In addition, there is a clear need for further research concerning the treatment of symptoms in this population, particularly with quality of life as an outcome.

Conclusion

Across all GOLD stages, chronic bronchitis symptoms are associated with worse pulmonary symptoms and significant impairment in quality of life. For patients with chronic bronchitis, the presence or absence of bronchiectasis is not

associated with a significant difference in SGRQ symptom scores. Symptoms of chronic bronchitis impose a heavy burden on patients and should be treated regardless of the presence or absence of underlying bronchiectasis.

Acknowledgments

The authors would like to acknowledge the assistance of the COPDGene data center.

Authors' Contributions:

Dr. McEvoy takes responsibility for the content of this manuscript including the data and analysis. Substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; has drafted the submitted article or revised it critically and substantially for important intellectual content; has provided final approval of the version to be published; has agreed to be accountable for all aspects of the work: OB, MX, SK, NW, GH, CM. Analysis and interpretation: OB, MX, SK, NW, GH, CM. Data acquisition: SK, NW. Drafting the manuscript for important intellectual content: OB, GH, CM.

Declaration of Interest

Gary Hansen is employed by RespirTech. Charlene McEvoy is a clinical advisor to RespirTech. No other authors have a conflict related to this manuscript.

References

1. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD). WHO website. Published October 2013. Accessed November 19, 2013. <http://www.who.int/mediacentre/factsheets/fs315/en/index.html>
2. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. *NCHS Data Brief*. 2018;(328). <https://www.cdc.gov/nchs/products/databriefs/db328.htm>
3. Croft JB, Wheaton AG, Liu Y, et al. Urban-rural county and state differences in chronic obstructive pulmonary disease - United States, 2015. *MMWR Morb Mortal Wkly Rep*. 2018; 67(7):205-211. doi: <https://doi.org/10.15585/mmwr.mm6707a1>
4. National Heart, Lung, and Blood Institute (NHLBI). Morbidity and mortality 2012 chart book on cardiovascular, lung, and blood diseases. NHLBI website. Published February 2012. Accessed January 2, 2019. https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf
5. National Heart, Lung, and Blood Institute (NHLBI). Morbidity and mortality 2009 chartbook on cardiovascular, lung, and blood diseases. NHLBI website. Published October 2009. Accessed January 2, 2019. https://ecopmc.files.wordpress.com/2012/04/2009_chartbook.pdf
6. Yawn BP, Mintz ML, Doherty DE. GOLD in practice: chronic obstructive pulmonary disease treatment and management in the primary care setting. *Int J Chron Obstruct Pulmon Dis*. 2021;16:289-299. doi: <https://doi.org/10.2147/COPD.S222664>
7. Criner RN, Han MK. COPD care in the 21st century: a public health priority. *Respir Care*. 2018;63(5):591-600. doi: <https://doi.org/10.4187/respcare.06276>
8. Kim V, Garfield JL, Grabianowski CL, et al. The effect of chronic sputum production on respiratory symptoms in severe COPD. *COPD*. 2011;8(2):114-120. doi: <https://doi.org/10.3109/15412555.2011.558546>
9. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. *Chest*. 2009;135(4):975-982. doi: <https://doi.org/10.1378/chest.08-2062>
10. de Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. *Eur Respir J*. 2012;40(1):28-36. doi: <https://doi.org/10.1183/09031936.00141611>
11. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. *Respir Res*. 2005;6:98. doi: <https://doi.org/10.1186/1465-9921-6-98>
12. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. *Eur Respir J*. 1995;8(8):1333-1338. doi: <https://doi.org/10.1183/09031936.95.08081333>
13. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. *Chest*. 2011;140(3):626-633. doi: <https://doi.org/10.1378/chest.10-2948>
14. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2013;187(3):228-237. doi: <https://doi.org/10.1164/rccm.201210-1843CI>
15. Barker AF. Bronchiectasis. *N Engl J Med*. 2002;346(18):1383-1393. doi: <https://doi.org/10.1056/NEJMra012519>
16. Polverino E, Dimakou K, Hurst J, et al. The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions. *Eur Respir J*. 2018;52:1800328. doi: <https://doi.org/10.1183/13993003.00328-2018>
17. Hurst JR, Elborn JS, De Soyza A. COPD-bronchiectasis overlap syndrome. *Eur Respir J*. 2015;45(2):310-313. doi: <https://doi.org/10.1183/09031936.00170014>
18. Stewart JI, Maselli DJ, Anzueto A, et al. Clinical impact of CT radiological feature of bronchiectasis in the COPDGene cohort. *Am J Crit Care Med*. 2012;185:A3656. doi: https://doi.org/10.1164/ajrcm-conference.2012.185.1_Meeting Abstracts.A3656
19. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. *COPD*. 2010;7(1):32-43. doi: <https://doi.org/10.3109/15412550903499522>
20. Diaz AA, Young TP, Maselli DJ, et al. Quantitative CT measures of bronchiectasis in smokers. *Chest*. 2017;151(6):1255-1262. doi: <https://doi.org/10.1016/j.chest.2016.11.024>
21. Maselli DJ, Bhatt SP, Anzueto A, et al. Clinical epidemiology of COPD - Insights from 10 years of the COPDGene study. *Chest*. 2019;156(2):228-238. doi: <https://doi.org/10.1016/j.chest.2019.04.135>
22. Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. *JAMA Intern Med*. 2015;175(9):1539-1549. doi: <https://doi.org/10.1001/jamainternmed.2015.2735>
23. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD website. Published 2019. Accessed January 2019. <http://goldcopd.org>
24. Kim V, Zhao H, Regan E, et al. The St George's Respiratory Questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition. *Chest*. 2019;156(4):685-695. doi: <https://doi.org/10.1016/j.chest.2019.03.041>
25. Ferris BG. Epidemiology standardization project (American Thoracic Society). *Am Rev Respir Dis*. 1978;118(6 Pt 2):1-120.

-
26. Kim V, Crapo J, Zhao H, et al. Comparison between an alternative and the classic definition of chronic bronchitis in COPD Gene. *Ann Am Thorac Soc*. 2015;12(3):332-339.
doi: <https://doi.org/10.1513/AnnalsATS.201411-518OC>
-
27. Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. *PLoS One*. 2016;11(3):e0150532.
doi: <https://doi.org/10.1371/journal.pone.0150532>
-
28. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2017;9:Cd002309.
doi: <https://doi.org/10.1002/14651858.CD002309.pub5>
-
29. Gao YH, Abo Leyah H, Finch S, et al. The relationship between symptoms, exacerbations, and treatment response in bronchiectasis. *Eur Respir J*. 2020;56(suppl 64):4104.
doi: <https://doi.org/10.1183/13993003.congress-2020.4104>
-
30. Janjua S, Fortescue R, Poole P. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2020;5:Cd002309.
doi: <https://doi.org/10.1002/14651858.CD002309.pub6>
-
31. Martin C, Frija-Masson J, Burgel PR. Targeting mucus hypersecretion: new therapeutic opportunities for COPD? *Drugs*. 2014;74(10):1073-1089. doi: <https://doi.org/10.1007/s40265-014-0235-3>
-
32. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J*. 2017;50(3):1700629.
doi: <https://doi.org/10.1183/13993003.00629-2017>
-
33. Rumback MJ, Marchione VL, Kennedy TC, Rolfe MW. Ninety-day assessment of the effect of high-frequency chest wall oscillation (HFCWO) on exercise tolerance and quality of life of patients with chronic obstructive pulmonary disease. *Chest*. 2001; 120:4(Suppl): 250S. (Presented at the 2001 ACCP Chest Conference November 2001).
-
34. van der Schans CP. Conventional chest physical therapy for obstructive lung disease. *Respir Care*. 2007;52(9):1198-1209.
doi: <http://rc.rcjournal.com/content/52/9/1198>
-
35. Farag T, EL-Syed M. Utility of vest high frequency chest wall oscillation device versus flutter device in acute exacerbation of chronic obstructive pulmonary disease. *Int J Res Med Sci*. 2018;6(1):1-9.
doi: <https://doi.org/10.18203/2320-6012.ijrms20175703>